Periventricular White Matter Hyperintensities in Cerebral Amyloid Angiopathy and Hypertensive Arteriopathy

NCT05486897 | Completed

• 1 other identifier: LOCAL/2022/DR-04
• Study Type: observational
• Target: 315
• Locations: 1 country
• Sites: 1

Brief Summary

White matter hyperintensities (WMH) are one of the small vessel disease-related MRI characteristics of both cerebral amyloid angiopathy (CAA) and hypertensive arteriopathy (HA). WMH tend to show a peri-basal ganglia pattern in HA, whereas a multiple subcortical spots pattern can be observed in CAA. Periventricular WMH (PVWMH) have been reported to be posterior predominant using a semiautomated segmentation method and logarithmic transformation, not used in daily clinical practice. In these studies including CAA patients, patients initially presented with haemorrhage-related symptoms. In another study analysing PVWMH and cerebral amyloid evidence in patients with mild cognitive impairment, frontal PVWMH burden was associated with high uptake on florbetapir-PET whereas parietal and occipital PVWMH burden was associated with low CSF-amyloid-beta. The aim of this study is the descriptive comparative analysis of the distribution of PVWMH between CAA and HA patients with radiological tools available in daily practice.

Conditions

Cerebral Amyloid Angiopathy; Hypertensive Arteriopathy

Outcome Measures

Primary Outcomes (12)

• Distribution of PVWMH

  Maximal distance between the outer PVWMH border and the border of the lateral ventricle (on the axis oriented at 90° to the border of the ventricle)

  Base line, Day 0

• Distribution of PVWMH - total PVWMH extent.

  The sum of the PVWMH measurements around the four ventricles horns (i.e. bilateral anterior and posteriors horns) resulted in total PVWMH extent.

  Base line, Day 0

• Corpus callosum (CC) WMH

  Distance between the border of the third ventricle and the outer border of the WMH on the rostro-caudal axis, resulting in anterior and posterior CC-PVWMH extent measurements.

  Base line, Day 0

• Corpus callosum (CC) WMH - total CC-PVWMH extent.

  The sum of the anterior and posterior CC-PVWMH measurements resulted in the total CC-PVWMH extent.

  Base line, Day 0

• Ratios

  Calcul of posterior/anterior ratios for both the PVWMH and CC-PVWMH

  base line, day 0

• Anterior PVWMH

  Comparison of anterior PVWMH between CAA group and HA group.

  Base line, Day 0

• Posterior PVWMH

  Comparison of posterior PVWMH between CAA group and HA group.

  Base line, Day 0

• Total PVWMH

  Comparison of total PVWMH between CAA group and HA group.

  Base line, Day 0

• Posterior/anterior PVWMH ratio

  Comparison of the posterior/anterior PVWMH ratio between CAA and HA groups.

  Base line, Day 0

• anterior CC-PVWMH

  Comparison of anterior CC-PVWMH between CAA group and HA group.

  Base line, Day 0

• Posterior CC-PVWMH

  Comparison of posterior CC-PVWMH between CAA group and HA group.

  Base line, Day 0

• Total PVWMH and posterior/anterior CC-PVWMH ratio

  Comparison of total PVWMH and posterior/anterior CC-PVWMH ratio between CAA group and HA group.

  Base line, Day 0

Study Arms (2)

cerebral amyloid angiopathy

Patient with cerebral amyloid angiopathy

Other: None, pure observational study

Hypertensive arteriopathy

Patients with hypertensive arteriopathy

Other: None, pure observational study

Interventions

None, pure observational study OTHER

None, pure observational study

Hypertensive arteriopathy; cerebral amyloid angiopathy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

CAA and HA patients, managed at Nîmes University Hospital between January 2015 and March 2022

You may qualify if:

• CAA and HA patients, managed at Nîmes University Hospital between January 2015 and March 2022.

You may not qualify if:

• CAA and HA patients, treated at the CHU of Nîmes between January 2015 and March 2022, not objecting to the use of their health data

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Nīmes: lead

Study Sites (1)

CHU de Nîmes

Nîmes, 30029, France

Location

Related Publications (1)

• Deasy L, Laurent-Chabalier S, Wacongne A, Parvu T, Mura T, Thouvenot E, Renard D. Diagnostic Accuracy of Posterior/Anterior Periventricular WMH Ratio to Differentiate CAA From Hypertensive Arteriopathy. Stroke. 2024 Aug;55(8):2086-2093. doi: 10.1161/STROKEAHA.123.046379. Epub 2024 Jun 26.

  PMID: 38920025 RESULT

MeSH Terms

Conditions

Cerebral Amyloid Angiopathy

Condition Hierarchy (Ancestors)

Cerebral Arterial Diseases; Intracranial Arterial Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Amyloidosis; Proteostasis Deficiencies; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• Anissa MEGZARI

  Centre Hospitalier Universitaire de Nīmes

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 2, 2022
• First Posted: August 4, 2022
• Study Start: September 5, 2022
• Primary Completion: December 15, 2023
• Study Completion: December 15, 2023
• Last Updated: December 4, 2025

Record last verified: 2024-01

Locations

FR (1)